Latest Healthcare News

Little Green Pharma has secured Federal Court approval for its full acquisition of Cannatrek, marking a key milestone in expanding its global medicinal cannabis footprint. The scheme became effective on 25 May 2026, with implementation set for 1 June.

IMEXHS has landed a significant public tender in Mexico, deploying its AI-powered Aquila+ radiology platform across 20 hospitals, adding $384,000 in new annual recurring revenue and advancing its Latin American expansion.

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.

Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

Radius Residential Care has syndicated its bank debt, boosting facility limits by NZD 30 million and cutting financing costs by 65 basis points to support its growth plans, including a new care home acquisition and development projects.

TruScreen Group has secured NZ$1.82 million through an oversubscribed placement, underscoring investor confidence amid its global cervical screening expansion. The company also announced a renounceable rights issue and attaching options, both subject to shareholder approval.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.

Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales after successfully defending against Cosette Pharmaceuticals’ claims tied to a terminated acquisition deal.

TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.

Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.